Key Highlights

  • NeOnc Technologies (NASDAQ:NTHI) finished Tuesday, November 10, 2026 at USD 4.47, a 19.52% advance from a calculated prior close of USD 3.74, which placed it among the leading gainers in a published screener snapshot covering 4,625 names.
  • Trading reached 129.08K shares, a relative Volume of 1.04, so the climb happened on near-typical activity that amounted to roughly USD 576,988 at the closing price (calculated).
  • The snapshot lists trailing diluted EPS of USD -1.95, EPS growth of +33.60%, no P/E ratio, a 0.00% Dividend Yield and a Market Value of USD 128.96 million.
  • Published coverage indicates the chief executive picked up 40,000 shares at an average of USD 3.39 on November 6, 2026, an outlay of USD 135,600 that raised his stake to 3,253,000 shares.

What Drove NeOnc Technologies Higher on November 10 (+19.52%)

The clinical-stage biotechnology company wrapped up the regular session at USD 4.47, a 19.52% advance. Basic arithmetic produces a calculated prior close near USD 3.74 for Monday, November 9, 2026, which means about USD 0.73 was added per share. Published coverage recorded Monday's open at USD 3.49, so the shares were already hovering close to their 50-day Moving Average of USD 3.33 before the jump. The USD 4.47 close remains well under the 200-day moving average of USD 5.38 and lies within a one-year range of USD 2.50 to USD 12.00, roughly 63% beneath the peak of that band (calculated). With 129.08K shares changing hands at a relative volume of 1.04, turnover stayed close to the recent norm.

The Rationale: No Catalyst Found, Insider Buying and Earnings Backdrop

Published coverage did not surface any company release, filing or trial announcement dated November 9 or 10, 2026, so the explanation is simply that no catalyst was identified. The previous week supplies some background. Results arrived on November 5, 2026, showing a loss of USD 0.28 per share compared with a consensus estimate of a USD 0.25 loss. The chief executive followed with a share purchase on November 6, and more Form 4 filings surfaced around November 9. Analyst opinion is divided, with coverage listing 4 buy, 1 hold and 1 sell ratings, a consensus target of USD 16.00 and a BTIG target of USD 15.00 dated September 8. In general terms, small biotech names can climb on insider purchases, upgrades or sector flows, yet these are broad mechanisms and not confirmed causes.

Valuation, Liquidity and Risks for NeOnc Technologies

Few valuation yardsticks apply here. No P/E exists because trailing diluted EPS sits at USD -1.95, though the loss shrank, with EPS growth of +33.60%. The dividend yield is 0.00%. A market value of USD 128.96 million points to roughly 28.85 million shares at USD 4.47 (calculated). Turnover near USD 576,988 is modest for a company this size, so a handful of trades can shift the price and bid-ask spreads may widen. Risks cover ongoing losses, the need to raise Capital for clinical programs, dilution from future share issuance, trial results and a share price still far under its USD 12.00 yearly high. Insider purchases offer no guarantee of future gains. Nothing here suggests the advance will persist.

Where Things Stand

NeOnc Technologies (NASDAQ:NTHI) advanced 19.52% to USD 4.47 on November 10, 2026, and published coverage points to no company news behind the move. The rise came on 129.08K shares, a relative volume of 1.04, from a calculated prior close of USD 3.74. Trailing EPS is USD -1.95, no dividend is paid, and the market value is USD 128.96 million. The recent insider purchase of 40,000 shares at USD 3.39 is background, not a confirmed cause.